Compare ABLV & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABLV | CALC |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | China | United States |
| Employees | 89 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.4M | 88.3M |
| IPO Year | N/A | 2020 |
| Metric | ABLV | CALC |
|---|---|---|
| Price | $0.64 | $0.56 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 5.4K | ★ 421.5K |
| Earning Date | 04-23-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.70 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.59 | $0.46 |
| 52 Week High | $1.77 | $7.20 |
| Indicator | ABLV | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 43.40 | 32.66 |
| Support Level | $0.60 | $0.49 |
| Resistance Level | $0.73 | $0.79 |
| Average True Range (ATR) | 0.03 | 0.08 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 25.75 | 11.52 |
Able View Global Inc operates as a brand management partner of international beauty and personal care brands in China. It provides full-service solutions covering marketing plan, branding, digital and social marketing, omni-channel sales, customer service, overseas logistics, warehouse, and fulfillment. The firm generates revenue from product sales by distributing and selling cross-border products from various brand owners to Chinese consumers.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.